FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sarada Gurubhagavatula

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Physiology

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Geoffrey Liu; Sarada Gurubhagavatula; Wei Zhou; Z Wang; Beow Y Yeap; K Asomaning; Li Su; C. Rebecca Suk Heist; Thomas J Lynch; David C Christiani
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Nathan A Pennell; Gilbert H Daniels; Robert I Haddad; Douglas S Ross; Tracey Evans; Lori J Wirth; Panos H Fidias; Jennifer S Temel; Sarada Gurubhagavatula; C. Rebecca Suk Heist; John R Clark; Thomas J Lynch
A phase II study of gefitinib in patients with advanced thyroid cancer.
Sarada Gurubhagavatula; Thomas J Lynch
The role of adjuvant chemotherapy for non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sarada Gurubhagavatula (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Geoffrey Liu; Sarada Gurubhagavatula; Wei Zhou; Z Wang; Beow Y Yeap; K Asomaning; Li Su; C. Rebecca Suk Heist; Thomas J Lynch; David C Christiani
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
The pharmacogenomics journal 2008;8(2):129-38.
2008: Nathan A Pennell; Gilbert H Daniels; Robert I Haddad; Douglas S Ross; Tracey Evans; Lori J Wirth; Panos H Fidias; Jennifer S Temel; Sarada Gurubhagavatula; C. Rebecca Suk Heist; John R Clark; Thomas J Lynch
A phase II study of gefitinib in patients with advanced thyroid cancer.
Thyroid : official journal of the American Thyroid Association 2008;18(3):317-23.
2005: Sarada Gurubhagavatula; Thomas J Lynch
The role of adjuvant chemotherapy for non-small cell lung cancer.
Seminars in respiratory and critical care medicine 2005;26(3):298-303.
2005: Rebecca Suk; Sarada Gurubhagavatula; Sohee Park; Wei Zhou; Li Su; Thomas J Lynch; John C Wain; Donna Neuberg; Geoffrey Liu; David C Christiani
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1534-8.
2004: Wei Zhou; Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Donna Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4939-43.
2004: Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Wei Zhou; Li Su; John C Wain; Thomas J Lynch; Donna Neuberg; David C Christiani
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2594-601.
2004: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia Neal; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeffrey Settleman; Daniel A Haber
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine 2004;350(21):2129-39.
2004: Pasi A Janne; Sarada Gurubhagavatula; Beow Y Yeap; Joan Lucca; Patricia Ostler; Arthur T Skarin; Panos Fidias; Thomas J Lynch; Bruce E Johnson
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Lung cancer (Amsterdam, Netherlands) 2004;44(2):221-30.